News Hong Kong biotechs IPOs face lower valuations after Ascletis... Biotechs taking an advantage of new Hong Kong exchange rules have been told to expect lower valuations, after Chinese pioneer Ascletis Pharma’s shares plunged nearly 45% in the first month
Views & Analysis Regulatory timelines in the Asia-Pacific Snapshot of clinical trial application processes in the region.
News Novartis preps key early breast cancer filing for Kisqali NATALEE trial readout sets up Kisqali as rival to Lilly's Verzenio as adjuvant treatment.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
